The Asia-Pacific Alzheimer’s disease therapeutics & diagnostics market is set to register a CAGR of 6.89% during the forecast period, 2022-2030, generating a revenue of $3541.75 million by 2030.

ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET FORECAST 2022-2030

Asia-Pacific Alzheimer’s Disease Market by Therapeutics & Diagnostics (Therapeutics (Drugs, Disease Stage, Generic & Branded) Diagnostics (Lumbar Puncture Test, Positron Emission Tomography, Electroencephalography, Magnetic Resonance Imaging, Computed Tomography, Blood Test, Other Diagnostics)) by Geography

Request free sample

The Asia-Pacific Alzheimer’s disease therapeutics & diagnostics market is set to register a CAGR of 6.89% during the forecast period, 2022-2030, generating a revenue of $3541.75 million by 2030.

The Asia-Pacific market is mainly driven by the constant rise in the population in developing countries such as India, China, and Japan, in turn impacting the growth of the aging population. Also, the rising prevalence of dementia, mainly in the semi-urban and rural provinces, boosts the Asia-Pacific Alzheimer’s disease therapeutics & diagnostics market. Further, the lack of effective and suitable treatment and the magnitude of the affected population offer opportunities for drug manufacturers.

Asia_Pacific_Alzheimer’s_Disease_Therapeutics_&_Diagnostics_Market

To know more about this report, request a free sample copy

The Asia-Pacific Alzheimer’s disease therapeutics & diagnostics market growth assessment includes the evaluation of Australia & New Zealand, India, Japan, India, Vietnam, Thailand, Indonesia, South Korea, China, and Rest of Asia-Pacific. In China, as the aging population is more prone to neurological disorders, such as dementia-associated Alzheimer’s disease, the China Alzheimer’s disease diagnostics & therapeutics market is expected to witness growth during the forecast period.

On the other hand, there is an ongoing R&D work in Alzheimer’s detection in Japan, and the overall understanding of the disease pathology has also picked up great momentum in the past few years. Although there is a lack of industry-funded R&D activity, academia has been producing quality R&D, which will likely result in commercially marketed products in the future. Further, Japan has a sophisticated long-term care insurance system, which is universal and funded partly by tax and insurance contributions. Moreover, Japan is also adopting new voluntary approaches to support the publicly funded healthcare provision.

The Asia-Pacific Alzheimer’s disease therapeutics & diagnostics market evaluation is segmented into therapeutics & diagnostics.

One of the essential parts of therapeutics is market drugs, which comprise NMDA receptor antagonists, Cholinesterase inhibitors, etc., and are used to treat Alzheimer’s. Moreover, several FDA-approved drugs are available to treat various stages of Alzheimer’s. The growth of global marketed drugs is driven by increasing demand for treatment due to the increasing prevalence of Alzheimer’s disease.

Furthermore, reports from the World Health Organization (WHO) reveal that about 60% of people living with dementia worldwide are from low or middle-income countries. The total number of people with dementia is estimated to be approximately 82 million in 2030 and 152 million in 2050. Moreover, ADI has also estimated that 58% of individuals with dementia reside in low to middle-income countries, which is expected to rise to 68% by 2050. Thus, with the increase in the prevalence of Alzheimer’s dementia, the demand for treatment is also increasing, thereby positively impacting the growth of the marketed drugs segment.

The key players in the Asia-Pacific Alzheimer’s disease therapeutics & diagnostics market are Lupin Limited, Sun Pharmaceuticals Industries Ltd, Novartis AG, GE Healthcare, etc.

Sun Pharmaceuticals Industries Ltd is one of the world’s largest generic pharmaceutical organizations and India’s top companies. The company has a vertically integrated business structure. It was founded in 1983. Since its foundation, the company has provided high-quality and cost-efficient drugs to around 150 countries. The company has 50 manufacturing units across 5 continents, R&D centers, and a workforce of more than 10,000 globally. The company has taken strategic initiatives to strengthen its business in Asia. Sun Pharma acquired the Novartis Japan business in 2016 and performed a merger with Ranbaxy in 2015. The company is headquartered in Mumbai, India.

Sun Pharmaceuticals’ Donepezil Hydrochloride tablets are used to treat Alzheimer’s disease. It is a 10 mg film-coated and generic version of drug major Eisai’s Aricept tablet.

Report Synopsis

Report ScopeDetails
Market Forecast Years2022-2030
Base Year2021
Market Historical Years2018-2021
Forecast UnitsRevenue ($ Million)
Segments AnalyzedTherapeutics & Diagnostics
Countries AnalyzedChina, Japan, India, South Korea, Indonesia, Thailand, Vietnam, Australia & New Zealand, and Rest of Asia-Pacific
Companies Analyzed

Allergan PLC, Amarantus, BioScience Holdings Inc, Baxter International Inc, Biogen Inc, Cognoptix Inc, Eisai Co Ltd, Eli Lilly & Company, F Hoffmann-La Roche, GE Healthcare, Johnson & Johnson, Lupin Limited, Merck & Co Inc, Novartis AG, Pfizer Inc, Siemens Healthineers AG, Sun Pharmaceuticals Industries Ltd, Teva Pharmaceutical Industries Limited, Zydus Cadila

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES
      • MARKET OVERVIEW
    3. MARKET DYNAMICS
      • PARENT MARKET ANALYSIS
      • KEY DRIVERS
        • GROWING GERIATRIC POPULATION
        • RISING PERVASIVENESS OF ALZHEIMER’S DISEASE
        • EMERGING NOVEL DIAGNOSTIC TECHNOLOGIES
        • INCREASING PIPELINE DRUGS
      • KEY RESTRAINTS
        • FAILURE OF THE LATE-STAGE DRUGS
        • STRINGENT GOVERNMENT REGULATIONS
        • LACK OF THE AVAILABILITY OF SURROGATE MARKERS
    1. KEY ANALYTICS
      • TIMELINE OF ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
      • PHASES AND STERNNESS OF ALZHEIMER’S DISEASE
      • IMPACT OF COVID-19 ON ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
      • KEY MARKET TRENDS
      • PORTER’S FIVE FORCES ANALYSIS
        • BUYERS POWER
        • SUPPLIERS POWER
        • SUBSTITUTION
        • NEW ENTRANTS
        • INDUSTRY RIVALRY
      • KEY BUYING CRITERIA
      • SUPPLY CHAIN ANALYSIS
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
    2. MARKET BY THERAPEUTICS & DIAGNOSTICS
      • THERAPEUTICS
        • DRUGS
          • MARKETED DRUGS
          • PIPELINE DRUGS
        • DISEASE STAGE
          • LATE-STAGE: SEVERE AD
          • EARLY/MIDDLE STAGE: MILD TO MODERATE AD
          • PRODROMAL STAGE
        • GENERIC & BRANDED
          • BRANDED
          • GENERIC
      • DIAGNOSTICS
        • LUMBAR PUNCTURE TEST
        • POSITRON EMISSION TOMOGRAPHY
        • ELECTROENCEPHALOGRAPHY
        • MAGNETIC RESONANCE IMAGING
        • COMPUTED TOMOGRAPHY
        • BLOOD TEST
        • OTHER DIAGNOSTICS
    1. GEOGRAPHICAL ANALYSIS
      • ASIA-PACIFIC
        • MARKET SIZE & ESTIMATES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        • COUNTRY ANALYSIS
          • CHINA
          • JAPAN
          • INDIA
          • SOUTH KOREA
          • INDONESIA
          • THAILAND
          • VIETNAM
          • AUSTRALIA & NEW ZEALAND
          • REST OF ASIA-PACIFIC
    1. COMPETITIVE LANDSCAPE
      • KEY STRATEGIC DEVELOPMENTS
        • MERGERS & ACQUISITIONS
        • PRODUCT LAUNCHES & DEVELOPMENTS
        • PARTNERSHIPS & AGREEMENTS
        • BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES
      • COMPANY PROFILES
        • ALLERGAN PLC (ACQUIRED BY ABBVIE)
        • AMARANTUS BIOSCIENCE HOLDINGS INC
        • BAXTER INTERNATIONAL INC
        • BIOGEN INC
        • COGNOPTIX INC
        • EISAI CO LTD
        • ELI LILLY & COMPANY
        • F HOFFMANN-LA ROCHE
        • GE HEALTHCARE
        • JOHNSON & JOHNSON
        • LUPIN LIMITED
        • MERCK & CO INC
        • NOVARTIS AG
        • PFIZER INC
        • SIEMENS HEALTHINEERS AG
        • SUN PHARMACEUTICALS INDUSTRIES LTD
        • TEVA PHARMACEUTICAL INDUSTRIES LIMITED
        • ZYDUS CADILA

    LIST OF TABLES

    TABLE 1: MARKET SNAPSHOT – ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS

    TABLE 2: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 3: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 4: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 5: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 6: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 7: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 8: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 9: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 10: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 11: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 12: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 13: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 14: LEADING PLAYERS OPERATING IN ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET

    TABLE 15: LIST OF MERGERS & ACQUISITIONS

    TABLE 16: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

    TABLE 17: LIST OF PARTNERSHIPS & AGREEMENTS

    TABLE 18: LIST OF BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES          

    LIST OF FIGURES

    FIGURE 1: PIPELINE DRUGS RELATED TO ALZHEIMER’S DISEASE

    FIGURE 2: KEY MARKET TRENDS

    FIGURE 3: PORTER’S FIVE FORCES ANALYSIS

    FIGURE 4: KEY BUYING CRITERIA

    FIGURE 5: SUPPLY CHAIN ANALYSIS

    FIGURE 6: OPPORTUNITY MATRIX

    FIGURE 7: VENDOR LANDSCAPE

    FIGURE 8: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY THERAPEUTICS & DIAGNOSTICS, IN 2021

    FIGURE 9: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2030 (IN $ MILLION)

    FIGURE 10: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DRUGS, IN 2021

    FIGURE 11: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2030 (IN $ MILLION)

    FIGURE 12: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2030 (IN $ MILLION)

    FIGURE 13: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DISEASE STAGE, IN 2021

    FIGURE 14: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE-STAGE: SEVERE AD, 2022-2030 (IN $ MILLION)

    FIGURE 15: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2022-2030 (IN $ MILLION)

    FIGURE 16: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2030 (IN $ MILLION)

    FIGURE 17: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY GENERIC & BRANDED, IN 2021

    FIGURE 18: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2030 (IN $ MILLION)

    FIGURE 19: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2030 (IN $ MILLION)

    FIGURE 20: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2030 (IN $ MILLION)

    FIGURE 21: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY DIAGNOSTICS, IN 2021

    FIGURE 22: ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2030 (IN $ MILLION)

    FIGURE 23: ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2022-2030 (IN $ MILLION)

    FIGURE 24: ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2030 (IN $ MILLION)

    FIGURE 25: ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2022-2030 (IN $ MILLION)

    FIGURE 26: ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2030 (IN $ MILLION)

    FIGURE 27: ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2030 (IN $ MILLION)

    FIGURE 28: ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2030 (IN $ MILLION)

    FIGURE 29: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

    FIGURE 30: CHINA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 31: JAPAN ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 32: INDIA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 33: SOUTH KOREA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 34: INDONESIA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 35: THAILAND ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 36: VIETNAM ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 37: AUSTRALIA & NEW ZEALAND ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 38: REST OF ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)       

    1. GEOGRAPHICAL ANALYSIS
      • ASIA-PACIFIC
        • MARKET SIZE & ESTIMATES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        • COUNTRY ANALYSIS
          • CHINA
          • JAPAN
          • INDIA
          • SOUTH KOREA
          • INDONESIA
          • THAILAND
          • VIETNAM
          • AUSTRALIA & NEW ZEALAND
          • REST OF ASIA-PACIFIC
    1. MARKET BY THERAPEUTICS & DIAGNOSTICS
      • THERAPEUTICS
        • DRUGS
          • MARKETED DRUGS
          • PIPELINE DRUGS
        • DISEASE STAGE
          • LATE-STAGE: SEVERE AD
          • EARLY/MIDDLE STAGE: MILD TO MODERATE AD
          • PRODROMAL STAGE
        • GENERIC & BRANDED
          • BRANDED
          • GENERIC
      • DIAGNOSTICS
        • LUMBAR PUNCTURE TEST
        • POSITRON EMISSION TOMOGRAPHY
        • ELECTROENCEPHALOGRAPHY
        • MAGNETIC RESONANCE IMAGING
        • COMPUTED TOMOGRAPHY
        • BLOOD TEST
        • OTHER DIAGNOSTICS

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type